Analysts Expect Oxford Immunotec Global PLC (OXFD) Will Announce Quarterly Sales of $33.56 Million

Equities research analysts forecast that Oxford Immunotec Global PLC (NASDAQ:OXFD) will announce $33.56 million in sales for the current fiscal quarter, Zacks Investment Research reports. Four analysts have made estimates for Oxford Immunotec Global’s earnings, with the highest sales estimate coming in at $33.74 million and the lowest estimate coming in at $33.39 million. Oxford Immunotec Global posted sales of $30.43 million in the same quarter last year, which suggests a positive year-over-year growth rate of 10.3%. The business is expected to announce its next quarterly earnings results on Tuesday, October 30th.

According to Zacks, analysts expect that Oxford Immunotec Global will report full year sales of $113.01 million for the current financial year, with estimates ranging from $112.82 million to $113.39 million. For the next financial year, analysts expect that the firm will report sales of $127.41 million, with estimates ranging from $125.28 million to $129.54 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that that provide coverage for Oxford Immunotec Global.

Oxford Immunotec Global (NASDAQ:OXFD) last posted its quarterly earnings results on Tuesday, July 31st. The company reported ($0.25) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.25). Oxford Immunotec Global had a negative net margin of 23.41% and a negative return on equity of 39.85%. The business had revenue of $29.32 million during the quarter, compared to the consensus estimate of $28.58 million. During the same quarter last year, the firm posted ($0.74) EPS. Oxford Immunotec Global’s revenue was up 12.3% compared to the same quarter last year.

Several research firms recently issued reports on OXFD. BidaskClub downgraded shares of Oxford Immunotec Global from a “hold” rating to a “sell” rating in a research report on Wednesday, July 11th. ValuEngine downgraded shares of Oxford Immunotec Global from a “hold” rating to a “sell” rating in a research report on Monday, July 30th. Finally, Zacks Investment Research raised shares of Oxford Immunotec Global from a “hold” rating to a “buy” rating and set a $16.00 price target for the company in a research report on Friday, August 3rd. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Oxford Immunotec Global presently has a consensus rating of “Buy” and an average price target of $17.80.

NASDAQ OXFD traded down $0.10 during mid-day trading on Wednesday, hitting $15.48. The company’s stock had a trading volume of 3,707 shares, compared to its average volume of 172,371. Oxford Immunotec Global has a twelve month low of $10.00 and a twelve month high of $19.19. The company has a current ratio of 5.39, a quick ratio of 4.86 and a debt-to-equity ratio of 0.41. The company has a market cap of $408.73 million, a P/E ratio of -11.38 and a beta of -0.21.

In other Oxford Immunotec Global news, CEO Peter Wrighton-Smith sold 86,100 shares of Oxford Immunotec Global stock in a transaction on Tuesday, September 25th. The shares were sold at an average price of $18.42, for a total transaction of $1,585,962.00. Following the transaction, the chief executive officer now directly owns 539,569 shares of the company’s stock, valued at approximately $9,938,860.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold a total of 146,100 shares of company stock worth $2,518,162 over the last ninety days. Insiders own 6.61% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of OXFD. Schwab Charles Investment Management Inc. boosted its holdings in Oxford Immunotec Global by 17.8% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 47,700 shares of the company’s stock worth $594,000 after acquiring an additional 7,200 shares during the last quarter. BlackRock Inc. raised its stake in shares of Oxford Immunotec Global by 6.9% during the 1st quarter. BlackRock Inc. now owns 1,162,510 shares of the company’s stock worth $14,474,000 after purchasing an additional 74,565 shares during the period. JPMorgan Chase & Co. raised its stake in shares of Oxford Immunotec Global by 258.0% during the 1st quarter. JPMorgan Chase & Co. now owns 19,554 shares of the company’s stock worth $243,000 after purchasing an additional 14,092 shares during the period. New York State Common Retirement Fund raised its stake in shares of Oxford Immunotec Global by 11.0% during the 1st quarter. New York State Common Retirement Fund now owns 58,581 shares of the company’s stock worth $729,000 after purchasing an additional 5,800 shares during the period. Finally, Russell Investments Group Ltd. raised its stake in shares of Oxford Immunotec Global by 28.1% during the 1st quarter. Russell Investments Group Ltd. now owns 81,375 shares of the company’s stock worth $1,013,000 after purchasing an additional 17,850 shares during the period. 92.44% of the stock is currently owned by hedge funds and other institutional investors.

Oxford Immunotec Global Company Profile

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for underserved immune-regulated conditions. Its development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology.

Featured Article: Average Daily Trade Volume Explained

Get a free copy of the Zacks research report on Oxford Immunotec Global (OXFD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Oxford Immunotec Global (NASDAQ:OXFD)

Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply